Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs

다국어 초록 (Multilingual Abstract)

The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the rates of complications and surgery. Although anti-TNF agents have changed the course of IBD, there are unmet needs in terms of primary and secondary non-responses and side effects such as infections and malignancies. Novel biologics and small-molecule drugs have been developed for IBD, and the medical treatment options have improved. These drugs include sphingosine-1-phosphate receptor modulators and anti-integrins to block immune cell migration, and cytokine and Janus kinase inhibitors to block immune cell communications. In this review, we discuss the approved novel biologics and small-molecule drugs, including several of those in the late stages of development, for the treatment of IBD.

참고문헌 (Reference)

1 나수영, "고령에서 염증성 장질환의 치료 – 무엇이 다르고 무엇을 알아야 하는가?" 대한소화기학회 77 (77): 231-240, 2021

2 Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies" 390 : 2769-2778, 2017

3 Milch C, "Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype" 264 : 123-126, 2013

4 Sands BE, "Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis" 381 : 1215-1226, 2019

5 Jovani M, "Vedolizumab for the treatment of IBD : a selective therapeutic approach targeting pathogenic a4b7cells" 14 : 1433-1443, 2013

6 Fares Ayoub, ; Matthew Odenwald ; Dejan Micic ; Sushila R. Dalal ; Joel Pekow ; Russell D. Cohen ; David T. Rubin ; Atsushi Sakuraba, "Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis" 대한장연구학회 20 (20): 240-250, 2022

7 Vitaliy Y. Poylin ; Jose Cataneo Serrato ; Jonathan Pastrana Del Valle ; Joseph D. Feuerstein, "Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study" 대한장연구학회 20 (20): 72-77, 2022

8 Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis" 369 : 699-710, 2013

9 Sands BE, "Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy" 23 : 97-106, 2017

10 Sandborn WJ, "Vedolizumab as induction and maintenance therapy for Crohn’s disease" 369 : 711-721, 2013

11 Sadik Saman ; Martin Goetz ; Judith Wendler ; Nisar P. Malek ; Jan Wehkamp ; Thomas Klag, "Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria" 대한장연구학회 17 (17): 340-348, 2019

12 Alexandra Cohen ; Najma Ahmed ; Ana Sant’Anna, "Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience" 대한장연구학회 19 (19): 217-224, 2021

13 Sands BE, "Ustekinumab as induction and maintenance therapy for ulcerative colitis" 381 : 1201-1214, 2019

14 Feagan BG, "Ustekinumab as induction and maintenance therapy for Crohn’s disease" 375 : 1946-1960, 2016

15 D’Haens G, "Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST Extension Study" 2021

16 Hanauer S, "Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis" 17 : 139-147, 2019

17 Satoshi Motoya ; Mamoru Watanabe ; Hyo Jong Kim ; Young Ho Kim ; 한동수 ; Hirotoshi Yuasa ; Junichi Tabira ; Naoki Isogawa ; Shoko Arai ; Isao Kawaguchi ; Toshifumi Hibi, "Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies" 대한장연구학회 16 (16): 233-245, 2018

18 Panes J, "Tofacitinib for induction and maintenance therapy of Crohn’s disease : results of two phase IIb randomised placebo-controlled trials" 66 : 1049-1059, 2017

19 Uzzan M, "Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis : a GETAID cohort" 54 : 312-319, 2021

20 Sandborn WJ, "Tofacitinib as induction and maintenance therapy for ulcerative colitis" 376 : 1723-1736, 2017

21 O’Sullivan C, "The structure and function of the S1P1receptor" 34 : 401-412, 2013

22 Colombel JF, "The safety of vedolizumab for ulcerative colitis and Crohn’s disease" 66 : 839-851, 2017

23 Murray PJ, "The JAK-STAT signaling pathway : input and output integration" 178 : 2623-2629, 2007

24 Vulliemoz M, "TNF-alpha blockers in inflammatory bowel diseases : practical recommendations and a user’s guide : an update" 101 (101): 16-26, 2020

25 Sanchez T, "Structural and functional characteristics of S1P receptors" 92 : 913-922, 2004

26 Papp K, "Safety surveillance for ustekinumab and other Psoriasis Treatments from the Psoriasis Longitudinal Assessment and Registry(PSOLAR)" 14 : 706-714, 2015

27 Sandborn WJ, "Safety of tofacitinib for treatment of ulcerative colitis, based on 4. 4 years of data from Global Clinical Trials" 17 : 1541-1550, 2019

28 Desai RJ, "Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study" 61 : 121-130, 2021

29 Tang MT, "Review article : nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease" 47 : 1440-1452, 2018

30 Lobaton T, "Review article : anti-adhesion therapies for inflammatory bowel disease" 39 : 579-594, 2014

31 Shuai K, "Regulation of JAK-STAT signalling in the immune system" 3 : 900-911, 2003

32 Emiko Mizoguchi ; Daren Low ; Yui Ezaki ; Toshiyuki Okada, "Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models" 대한장연구학회 18 (18): 151-167, 2020

33 Feagan BG, "Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases" 17 : 130-138, 2019

34 Hiromichi Shimizu ; Toshimitsu Fujii ; Shuji Hibiya ; Maiko Motobayashi ; Kohei Suzuki ; Kento Takenaka ; Eiko Saito ; Masakazu Nagahori ; Kazuo Ohtsuka ; Mamoru Watanabe, "Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis" 대한장연구학회 19 (19): 115-118, 2021

35 Langer-Gould A, "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab" 353 : 375-381, 2005

36 Kleinschmidt-DeMasters BK, "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis" 353 : 369-374, 2005

37 Jamilya Kaibullayeva ; Aliya Ualiyeva ; Ainash Oshibayeva ; Anar Dushpanova ; John K. Marshall, "Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study" 대한장연구학회 18 (18): 430-437, 2020

38 D’Amico F, "Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis" 16 : 835-844, 2022

39 Hiroyuki Okamoto ; Nathanael L. Dirks ; Maria Rosario ; Tetsuharu Hori ; Toshifumi Hibi, "Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease" 대한장연구학회 19 (19): 95-105, 2021

40 Brossard P, "Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-inhuman study" 76 : 888-896, 2013

41 Soo-Young Na ; Won Moon, "Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease" 거트앤리버 소화기연관학회협의회 13 (13): 604-616, 2019

42 Mullershausen F, "Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors" 5 : 428-434, 2009

43 Razieh Ardali ; Nasrin Kazemipour ; Saeed Nazifi ; Kamran Bagheri Lankarani ; Iman Razeghian Jahromi ; Masood Sepehrimanesh, "Pathophysiological role of Atg5 in human ulcerative colitis" 대한장연구학회 18 (18): 421-429, 2020

44 Scott FL, "Ozanimod(RPC1063)is a potent sphingosine-1-phosphate receptor-1(S1P1)and receptor-5(S1P5)agonist with autoimmune disease-modifying activity" 173 : 1778-1792, 2016

45 Feagan BG, "Ozanimod induction therapy for patients with moderate to severe Crohn’s disease : a single-arm, phase 2, prospective observer-blinded endpoint study" 5 : 819-828, 2020

46 Sandborn WJ, "Ozanimod induction and maintenance treatment for ulcerative colitis" 374 : 1754-1762, 2016

47 Sandborn WJ, "Ozanimod as induction and maintenance therapy for ulcerative colitis" 385 : 1280-1291, 2021

48 Hyo Sun Lee ; Soo-Kyung Park ; Dong Il Park, "Novel treatments for inflammatory bowel disease" 대한내과학회 33 (33): 20-27, 2018

49 Olivera P, "Next generation of small molecules in inflammatory bowel disease" 66 : 199-209, 2017

50 송은미 ; 양석균, "Natural history of inflammatory bowel disease: a comparison between the East and the West" 대한장연구학회 20 (20): 418-430, 2022

51 Sandborn WJ, "Natalizumab induction and maintenance therapy for Crohn’s disease" 353 : 1912-1925, 2005

52 Targan SR, "Natalizumab for the treatment of active Crohn’s disease : results of the ENCORE Trial" 132 : 1672-1683, 2007

53 Roda G, "Loss of response to anti-TNFs : definition, epidemiology, and management" 7 : e135-, 2016

54 Loftus EV Jr, "Long-term safety of vedolizumab for inflammatory bowel disease" 52 : 1353-1365, 2020

55 Vermeire S, "Long-term safety and efficacy of etrasimod for ulcerative colitis : results from the Open-label Extension of the OASIS Study" 15 : 950-959, 2021

56 Sandborn WJ, "Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy" 48 : 65-77, 2018

57 Sandborn WJ, "Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis : results from the open-label extension of the randomized, phase 2 TOUCHSTONE Study" 15 : 1120-1129, 2021

58 Su Jin Choi ; Ji Seon Oh ; Seokchan Hong ; Chang-Keun Lee ; Bin Yoo ; Yong-Gil Kim, "Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study" 대한내과학회 35 (35): 723-731, 2020

59 Ghoreschi K, "Janus kinases in immune cell signaling" 228 : 273-287, 2009

60 Samanen JC, "Introduction to Biological and Small Molecule Drug Research and Development" Elsevier 161-203, 2013

61 Mahadevan U, "Inflammatory bowel disease in pregnancy clinical care pathway : a report from the American Gastroenterological Association IBD Parenthood Project Working Group" 156 : 1508-1524, 2019

62 Feagan BG, "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease : a randomised, double-blind, placebo-controlled phase 2 study" 389 : 1699-1709, 2017

63 Yoon Suk Jung ; Minkyung Han ; Sohee Park ; Jae Hee Cheon, "Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study" 대한내과학회 35 (35): 1104-1113, 2020

64 Feagan BG, "Filgotinib as induction and maintenance therapy for ulcerative colitis(SELECTION) : a phase 2b/3 double-blind, randomised, placebo-controlled trial" 397 : 2372-2384, 2021

65 U.S. Food and Drug Administration, "FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions" FDA

66 Danese S, "Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis(GARDENIA) : a randomised, double-blind, double-dummy, phase 3 study" 7 : 118-127, 2022

67 Rubin DT, "Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis(HIBISCUS) : two phase 3randomised, controlled trials" 7 : 17-27, 2022

68 Vermeire S, "Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis(LAUREL) : a randomised, placebo-controlled, double-blind, phase 3 study" 7 : 28-37, 2022

69 Peyrin-Biroulet L, "Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors(HICKORY) : a phase 3, randomised, controlled trial" 7 : 128-140, 2022

70 Güray Can ; Emrah Poşul ; Bülent Yılmaz ; Hatice Can ; Uğur Korkmaz ; Fatih Ermiş ; Mevlüt Kurt ; Ülkü Dağlı, "Epidemiologic features of ınflammatory bowel disease in Western Blacksea region of Turkey for the last 10 years: retrospective cohort study" 대한내과학회 34 (34): 519-529, 2019

71 Feagan BG, "Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists" 15 : 229-239, 2017

72 Sandborn WJ, "Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis" 158 : 2139-2149, 2020

73 Choon Jin Ooi ; Ida Normiha Hilmi ; 김효종 ; Umesh Jalihal ; Deng Chyang Wu ; Dirk Demuth ; Dirk Lindner ; Shashi Adsul, "Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study" 대한장연구학회 19 (19): 71-82, 2021

74 Rupa Banerjee ; Sai Wei Chuah ; Ida Normiha Hilmi ; Deng Chyang Wu ; 양석균 ; Dirk Demuth ; Dirk Lindner ; Shashi Adsul, "Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study" 대한장연구학회 19 (19): 83-94, 2021

75 Toshifumi Hibi ; Yuya Imai ; Yoko Murata ; Nobuko Matsushima ; Richuan Zheng ; Christopher Gasink, "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies" 대한장연구학회 15 (15): 475-486, 2017

76 Tadakazu Hisamatsu ; 김효종 ; Satoshi Motoya ; Yasuo Suzuki ; Yoshifumi Ohnishi ; Noriyuki Fujii ; Nobuko Matsushima ; Richuan Zheng ; Colleen W. Marano, "Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)" 대한장연구학회 19 (19): 386-397, 2021

77 Sandborn WJ, "Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease" 158 : 2123-2138, 2020

78 Sandborn WJ, "Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis" 158 : 537-549, 2020

79 Sands BE, "Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease" 162 : 495-508, 2022

80 Sandborn WJ, "Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis" 20 : 1821-1830, 2022

81 Sandborn WJ, "Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis" 158 : 550-561, 2020

82 Sandborn WJ, "Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis" 20 : 105-115, 2022

83 Sands BE, "Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease : a phase 2a study" 153 : 77-86, 2017

84 Schwartz DA, "Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease : ENTERPRISE Study" 20 : 1059-1067, 2022

85 Sands BE, "Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed" 147 : 618-627, 2014

86 Menter A, "Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis : results from the Psoriasis Longitudinal Assessment and Registry(PSOLAR)" 30 : 1148-1158, 2016

87 Wittig BM, "Drug evaluation : CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases" 8 : 947-954, 2007

88 Benson JM, "Discovery and mechanism of ustekinumab : a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders" 3 : 535-545, 2011

89 del Pilar Martin M, "Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab" 65 : 1596-1603, 2008

90 Sokol H, "Complications and surgery in the inflammatory bowel diseases biological era" 30 : 378-384, 2014

91 Seung Wook Hong ; Jaewoo Park ; Hyuk Yoon ; Hye Ran Yang ; Cheol Min Shin ; Young Soo Park ; Nayoung Kim ; Dong Ho Lee ; Joo Sung Kim, "Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease" 대한내과학회 36 : 9-17, 2021

92 Ajit Sood ; Kirandeep Kaur ; Ramit Mahajan ; Vandana Midha ; Arshdeep Singh ; Sarit Sharma ; Amarender Singh Puri ; Bhabhadev Goswami ; Devendra Desai ; C. Ganesh Pai ; Kiran Peddi ; Mathew Philip ; Rakesh Kochhar ; Sandeep Nijhawan ; Shobna Bhatia ; N. Sridhara Rao, "Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry" 대한장연구학회 19 (19): 206-216, 2021

93 Vermeire S, "Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib(the FITZROY study) : results from a phase 2, double-blind, randomised, placebo-controlled trial" 389 : 266-275, 2017

94 Kim J, "Clinical outcomes and response predictors of vedolizumab induction treatment for Korean patients with inflammatory bowel diseases who failed anti-TNF therapy : a KASID prospective multicenter cohort study" 27 : 1931-1941, 2021

95 Jong Pil Im ; Byong Duk Ye ; You Sun Kim ; Joo Sung Kim, "Changing treatment paradigms for the management of inflammatory bowel disease" 대한내과학회 33 (33): 28-35, 2018

96 Ytterberg SR, "Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis" 386 : 316-326, 2022